208 related articles for article (PubMed ID: 25353961)
1. Beneficial effects of proanthocyanidins in the cardiac alterations induced by aldosterone in rat heart through mineralocorticoid receptor blockade.
Martín-Fernández B; de las Heras N; Valero-Muñoz M; Ballesteros S; Yao YZ; Stanton PG; Fuller PJ; Lahera V
PLoS One; 2014; 9(10):e111104. PubMed ID: 25353961
[TBL] [Abstract][Full Text] [Related]
2. Proanthocyanidins block aldosterone-dependent up-regulation of cardiac gamma ENaC and Nedd4-2 inactivation via SGK1.
Galiana-Simal A; Olivares-Álvaro E; Klett-Mingo M; Ruiz-Roso MB; Ballesteros S; de Las Heras N; Fuller PJ; Lahera V; Martín-Fernández B
J Nutr Biochem; 2016 Nov; 37():13-19. PubMed ID: 27592201
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1.
Martín-Fernández B; de las Heras N; Miana M; Ballesteros S; Valero-Muñoz M; Vassallo D; Davel AP; Rossoni LV; Cachofeiro V; Lahera V
Exp Physiol; 2012 Jun; 97(6):710-8. PubMed ID: 22327331
[TBL] [Abstract][Full Text] [Related]
4. Structural, functional, and molecular alterations produced by aldosterone plus salt in rat heart: association with enhanced serum and glucocorticoid-regulated kinase-1 expression.
Martín-Fernández B; de las Heras N; Miana M; Ballesteros S; Delgado C; Song S; Hintze T; Cachofeiro V; Lahera V
J Cardiovasc Pharmacol; 2011 Jan; 57(1):114-21. PubMed ID: 20980916
[TBL] [Abstract][Full Text] [Related]
5. The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes.
Gravez B; Tarjus A; Jimenez-Canino R; El Moghrabi S; Messaoudi S; Alvarez de la Rosa D; Jaisser F
PLoS One; 2013; 8(9):e73737. PubMed ID: 24040049
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and prevents oxidative stress in uremic rats.
Michea L; Villagrán A; Urzúa A; Kuntsmann S; Venegas P; Carrasco L; Gonzalez M; Marusic ET
Hypertension; 2008 Aug; 52(2):295-300. PubMed ID: 18591458
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans.
Hosoya K; Minakuchi H; Wakino S; Fujimura K; Hasegawa K; Komatsu M; Yoshifuji A; Futatsugi K; Shinozuka K; Washida N; Kanda T; Tokuyama H; Hayashi K; Itoh H
Kidney Int; 2015 Apr; 87(4):749-60. PubMed ID: 25337775
[TBL] [Abstract][Full Text] [Related]
8. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: Beneficial effects of mineralocorticoid receptor blocker.
Ohtani T; Ohta M; Yamamoto K; Mano T; Sakata Y; Nishio M; Takeda Y; Yoshida J; Miwa T; Okamoto M; Masuyama T; Nonaka Y; Hori M
Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R946-54. PubMed ID: 17023667
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
[TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
[TBL] [Abstract][Full Text] [Related]
11. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1.
Shibata S; Nagase M; Yoshida S; Kawachi H; Fujita T
Hypertension; 2007 Feb; 49(2):355-64. PubMed ID: 17200434
[TBL] [Abstract][Full Text] [Related]
12. Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats.
Martín-Fernández B; Rubio-Navarro A; Cortegano I; Ballesteros S; Alía M; Cannata-Ortiz P; Olivares-Álvaro E; Egido J; de Andrés B; Gaspar ML; de Las Heras N; Lahera V; Moreno JA
PLoS One; 2016; 11(1):e0145946. PubMed ID: 26730742
[TBL] [Abstract][Full Text] [Related]
13. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
Arai K; Tsuruoka H; Homma T
Eur J Pharmacol; 2015 Dec; 769():266-73. PubMed ID: 26607463
[TBL] [Abstract][Full Text] [Related]
14. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.
Luther JM; Luo P; Wang Z; Cohen SE; Kim HS; Fogo AB; Brown NJ
Kidney Int; 2012 Sep; 82(6):643-51. PubMed ID: 22622494
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats.
Nakano S; Kobayashi N; Yoshida K; Ohno T; Matsuoka H
Hypertens Res; 2005 Nov; 28(11):925-36. PubMed ID: 16555582
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
[TBL] [Abstract][Full Text] [Related]
17. SGK1-dependent cardiac CTGF formation and fibrosis following DOCA treatment.
Vallon V; Wyatt AW; Klingel K; Huang DY; Hussain A; Berchtold S; Friedrich B; Grahammer F; Belaiba RS; Görlach A; Wulff P; Daut J; Dalton ND; Ross J; Flögel U; Schrader J; Osswald H; Kandolf R; Kuhl D; Lang F
J Mol Med (Berl); 2006 May; 84(5):396-404. PubMed ID: 16604333
[TBL] [Abstract][Full Text] [Related]
18. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology.
Wilkinson-Berka JL; Tan G; Jaworski K; Harbig J; Miller AG
Circ Res; 2009 Jan; 104(1):124-33. PubMed ID: 19038868
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Du J; Fan YY; Hitomi H; Kiyomoto H; Kimura S; Kong CZ; Noma T; Kohno M; Nishiyama A; Nakano D
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F802-8. PubMed ID: 19535572
[TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid Receptor Blockade Improves Insulin Sensitivity in the Rat Heart and a Possible Molecular Mechanism.
Wang M; Li Y; Zhou K; Zhang G; Wang Y; Liu T; Zhang Y; Guo A; An Y
Cell Physiol Biochem; 2016; 39(3):860-70. PubMed ID: 27497962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
